Reynolds KS - Search Results

1

A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.

Ren YR, Golding A, Sorbello A, Ji P, Chen J, Saluja B, Witzmann K, Arya V, Reynolds KS, Choi SY, Nikolov NP, Sahajwalla C. Ren YR, et al. Among authors: reynolds ks. J Clin Pharmacol. 2020 Aug;60(8):954-975. doi: 10.1002/jcph.1673. Epub 2020 Jun 24. J Clin Pharmacol. 2020. PMID: 32469437 Free PMC article. Review.

2

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.

Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, Sahajwalla C, Huang SM, Lesko LJ. Davit B, et al. J Clin Pharmacol. 1999 Sep;39(9):899-910. doi: 10.1177/00912709922008515. J Clin Pharmacol. 1999. PMID: 10471980

3

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.

Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Gil Berglund E, Lesko LJ, Huang SM. Zhao P, et al. Among authors: reynolds ks. Clin Pharmacol Ther. 2011 Feb;89(2):259-67. doi: 10.1038/clpt.2010.298. Epub 2010 Dec 29. Clin Pharmacol Ther. 2011. PMID: 21191381

4

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, Arya V, Berglund EG, Atkinson AJ Jr, Sugiyama Y, Pang KS, Reynolds KS, Abernethy DR, Zhang L, Lesko LJ, Huang SM. Zhao P, et al. Among authors: reynolds ks. J Clin Pharmacol. 2012 Jan;52(1 Suppl):91S-108S. doi: 10.1177/0091270011415528. J Clin Pharmacol. 2012. PMID: 22232759

5

Does an increase in serum creatinine always reflect renal injury? The case of Stribild®.

Arya V, Florian J, Marcus KA, Reynolds KS, Lewis LL, Sherwat AI. Arya V, et al. Among authors: reynolds ks. J Clin Pharmacol. 2013 Nov 8. doi: 10.1002/jcph.223. Online ahead of print. J Clin Pharmacol. 2013. PMID: 24214102

6

Combining forces to combat infectious diseases.

Reynolds KS. Reynolds KS. Clin Pharmacol Ther. 2014 Aug;96(2):123-6. doi: 10.1038/clpt.2014.119. Clin Pharmacol Ther. 2014. PMID: 25056386

7

Justification of noninferiority margin: methodology considerations in an exposure-response analysis.

Wang Y, Harigaya Y, Cavaillé-Coll M, Colangelo P, Reynolds KS. Wang Y, et al. Among authors: reynolds ks. Clin Pharmacol Ther. 2015 Apr;97(4):404-10. doi: 10.1002/cpt.44. Epub 2015 Feb 13. Clin Pharmacol Ther. 2015. PMID: 25670256

8

Developing and Using Therapeutics for Emerging Infections.

McCune JS, Reynolds KS. McCune JS, et al. Among authors: reynolds ks. Clin Pharmacol Ther. 2015 Oct;98(4):346-51. doi: 10.1002/cpt.183. Clin Pharmacol Ther. 2015. PMID: 26179402 Free PMC article.

9

Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.

Florian J, Mishra P, Arya V, Harrington P, Connelly S, Reynolds KS, Sinha V. Florian J, et al. Among authors: reynolds ks. Clin Pharmacol Ther. 2015 Oct;98(4):394-402. doi: 10.1002/cpt.185. Epub 2015 Aug 31. Clin Pharmacol Ther. 2015. PMID: 26179495 Review.

10

Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective.

Arya V, Zhao P, Reynolds KS, Mishra P, Younis IR. Arya V, et al. Among authors: reynolds ks. Clin Pharmacol Ther. 2017 Oct;102(4):578-580. doi: 10.1002/cpt.699. Epub 2017 Apr 26. Clin Pharmacol Ther. 2017. PMID: 28444890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page